| Year |
Citation |
Score |
| 2023 |
Kurth V, Ogorek I, Münch C, Lopez-Rios J, Ousson S, Lehmann S, Nieweg K, Roebroek AJM, Pietrzik CU, Beher D, Weggen S. Pathogenic Aβ production by heterozygous PSEN1 mutations is intrinsic to the mutant protein and not mediated by conformational hindrance of wild type PSEN1. The Journal of Biological Chemistry. 104997. PMID 37394008 DOI: 10.1016/j.jbc.2023.104997 |
0.648 |
|
| 2023 |
Klecker PH, Fritzen L, Mazura AD, Weggen S, Pietrzik CU. Antibody-mediated inhibition of tissue-type plasminogen activator binding to the low-density lipoprotein receptor-related protein 1 as a potential beneficial modulator for stroke therapy. Journal of Cellular Biochemistry. PMID 37288821 DOI: 10.1002/jcb.30431 |
0.558 |
|
| 2023 |
Bader AS, Gnädig MU, Fricke M, Büschgens L, Berger LJ, Klafki HW, Meyer T, Jahn O, Weggen S, Wirths O. Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice. Life (Basel, Switzerland). 13. PMID 37109582 DOI: 10.3390/life13041053 |
0.388 |
|
| 2022 |
Mazura AD, Ohler A, Storck SE, Kurtyka M, Scharfenberg F, Weggen S, Becker-Pauly C, Pietrzik CU. PCSK9 acts as a key regulator of Aβ clearance across the blood-brain barrier. Cellular and Molecular Life Sciences : Cmls. 79: 212. PMID 35344086 DOI: 10.1007/s00018-022-04237-x |
0.655 |
|
| 2022 |
Marengo L, Armbrust F, Schoenherr C, Storck SE, Schmitt U, Zampar S, Wirths O, Altmeppen H, Glatzel M, Kaether C, Weggen S, Becker-Pauly C, Pietrzik CU. Meprin β knockout reduces brain Aβ levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimer's disease. Cellular and Molecular Life Sciences : Cmls. 79: 168. PMID 35235058 DOI: 10.1007/s00018-022-04205-5 |
0.66 |
|
| 2021 |
Stazi M, Lehmann S, Sakib MS, Pena-Centeno T, Büschgens L, Fischer A, Weggen S, Wirths O. Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis. Cellular and Molecular Life Sciences : Cmls. 79: 55. PMID 34913091 DOI: 10.1007/s00018-021-04062-8 |
0.315 |
|
| 2021 |
Aichholzer F, Klafki HW, Ogorek I, Vogelgsang J, Wiltfang J, Scherbaum N, Weggen S, Wirths O. Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease. Alzheimer's Research & Therapy. 13: 94. PMID 33947460 DOI: 10.1186/s13195-021-00828-1 |
0.345 |
|
| 2018 |
Walter S, Jumpertz T, Hüttenrauch M, Ogorek I, Gerber H, Storck SE, Zampar S, Dimitrov M, Lehmann S, Lepka K, Berndt C, Wiltfang J, Becker-Pauly C, Beher D, Pietrzik CU, ... ... Weggen S, et al. The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. Acta Neuropathologica. PMID 30426203 DOI: 10.1007/S00401-018-1929-5 |
0.695 |
|
| 2018 |
Hüttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, Wiltfang J, Wirths O. Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. Acta Neuropathologica Communications. 6: 108. PMID 30340518 DOI: 10.1186/S40478-018-0612-3 |
0.458 |
|
| 2018 |
Storck SE, Hartz AMS, Bernard J, Wolf A, Kachlmeier A, Mahringer A, Weggen S, Pahnke J, Pietrzik CU. The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM. Brain, Behavior, and Immunity. PMID 30041013 DOI: 10.1016/J.Bbi.2018.07.017 |
0.679 |
|
| 2018 |
Lesuis SL, Weggen S, Baches S, Lucassen PJ, Krugers HJ. Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice. Translational Psychiatry. 8: 53. PMID 29491368 DOI: 10.1038/S41398-018-0101-2 |
0.37 |
|
| 2018 |
Goel P, Jumpertz T, Tichá A, Ogorek I, Mikles DC, Hubalek M, Pietrzik CU, Strisovsky K, Schmidt B, Weggen S. Discovery and validation of 2-styryl substituted benzoxazin-4-ones as a novel scaffold for rhomboid protease inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 29463448 DOI: 10.1016/J.Bmcl.2018.02.017 |
0.591 |
|
| 2017 |
Goel P, Jumpertz T, Mikles DC, Tichá A, Nguyen MTN, Verhelst S, Hubalek M, Johnson DC, Bachovchin DA, Ogorek I, Pietrzik CU, Strisovsky K, Schmidt B, Weggen S. Discovery and Biological Evaluation of Potent and Selective N-Methylene Saccharin-Derived Inhibitors for Rhomboid Intramembrane Proteases. Biochemistry. PMID 29185711 DOI: 10.1021/Acs.Biochem.7B01066 |
0.595 |
|
| 2017 |
Wirths O, Walter S, Kraus I, Klafki HW, Stazi M, Oberstein TJ, Ghiso J, Wiltfang J, Bayer TA, Weggen S. N-truncated Aβ4-x peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models. Alzheimer's Research & Therapy. 9: 80. PMID 28978359 DOI: 10.1186/S13195-017-0309-Z |
0.495 |
|
| 2017 |
Lucassen PJ, Lesuis SL, Weggen S, Baches S, Krugers HJ. Early Life Stress Accelerates Amyloid Pathology And Cognitive Decline In Appswe/Ps1De9 Mice, But Can Be Rescued By Briefly Blocking Glucocorticoid Receptors At Middle Age Alzheimers & Dementia. 13: 1479. DOI: 10.1016/J.Jalz.2017.07.555 |
0.304 |
|
| 2016 |
Hüttenrauch M, Walter S, Kaufmann M, Weggen S, Wirths O. Limited Effects of Prolonged Environmental Enrichment on the Pathology of 5XFAD Mice. Molecular Neurobiology. PMID 27734334 DOI: 10.1007/S12035-016-0167-X |
0.428 |
|
| 2016 |
Schönherr C, Bien J, Isbert S, Wichert R, Prox J, Altmeppen H, Kumar S, Walter J, Lichtenthaler SF, Weggen S, Glatzel M, Becker-Pauly C, Pietrzik CU. Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site. Molecular Neurodegeneration. 11: 19. PMID 26895626 DOI: 10.1186/S13024-016-0084-5 |
0.667 |
|
| 2016 |
Storck S, Vandenbroucke RE, Weggen S, Schwaninger M, Bayer T, Pietrzik CU. O4-11-05: Endothelial-LRP1 Clears Major Amounts of Abeta 1-42 Across the Blood-Brain Barrier Alzheimer's & Dementia. 12: P361-P362. DOI: 10.1016/J.Jalz.2016.06.670 |
0.618 |
|
| 2015 |
Antonios G, Borgers H, Richard BC, Brauß A, Meißner J, Weggen S, Pena V, Pillot T, Davies SL, Bakrania P, Matthews D, Brownlees J, Bouter Y, Bayer TA. Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X. Scientific Reports. 5: 17338. PMID 26626428 DOI: 10.1038/Srep17338 |
0.36 |
|
| 2015 |
Storck SE, Meister S, Nahrath J, Meißner JN, Schubert N, Di Spiezio A, Baches S, Vandenbroucke RE, Bouter Y, Prikulis I, Korth C, Weggen S, Heimann A, Schwaninger M, Bayer TA, et al. Endothelial LRP1 transports amyloid-β1-42 across the blood-brain barrier. The Journal of Clinical Investigation. PMID 26619118 DOI: 10.1172/Jci81108 |
0.672 |
|
| 2015 |
Rabiej VK, Pflanzner T, Wagner T, Götze K, Storck S, Eble JA, Weggen S, Mueller-Klieser W, Pietrzik CU. Low density lipoprotein receptor-related protein 1 mediated endocytosis of β1-integrin influences cell adhesion and cell migration. Experimental Cell Research. PMID 26610862 DOI: 10.1016/J.Yexcr.2015.11.020 |
0.586 |
|
| 2015 |
Meister S, Storck SE, Hameister E, Behl C, Weggen S, Clement AM, Pietrzik CU. Expression of the ALS-causing variant hSOD1(G93A) leads to an impaired integrity and altered regulation of claudin-5 expression in an in vitro blood-spinal cord barrier model. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 35: 1112-21. PMID 25853911 DOI: 10.1038/Jcbfm.2015.57 |
0.581 |
|
| 2015 |
Richard BC, Kurdakova A, Baches S, Bayer TA, Weggen S, Wirths O. Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 45: 1223-36. PMID 25697701 DOI: 10.3233/Jad-143120 |
0.301 |
|
| 2015 |
Flesch D, Ness J, Lamers C, Dehm F, Popella S, Steri R, Ogorek I, Hieke M, Dannhardt G, Werz O, Weggen S, Schubert-Zsilavecz M. SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease. Bioorganic & Medicinal Chemistry Letters. 25: 841-6. PMID 25575659 DOI: 10.1016/J.Bmcl.2014.12.073 |
0.377 |
|
| 2015 |
Hüttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 44: 1291-302. PMID 25408216 DOI: 10.3233/Jad-142463 |
0.437 |
|
| 2014 |
Gowert NS, Donner L, Chatterjee M, Eisele YS, Towhid ST, Münzer P, Walker B, Ogorek I, Borst O, Grandoch M, Schaller M, Fischer JW, Gawaz M, Weggen S, Lang F, et al. Blood platelets in the progression of Alzheimer's disease. Plos One. 9: e90523. PMID 24587388 DOI: 10.1371/Journal.Pone.0090523 |
0.412 |
|
| 2014 |
Richard BC, Baches S, Weggen S, Bayer TA. The Impact Of Passsive Immunization Against N-Terminally Truncated Ab Species: A Comparative Study In The 5Xfad Alzheimer'S Model Alzheimers & Dementia. 10: 468. DOI: 10.1016/J.Jalz.2014.05.665 |
0.306 |
|
| 2013 |
Meister S, Zlatev I, Stab J, Docter D, Baches S, Stauber RH, Deutsch M, Schmidt R, Ropele S, Windisch M, Langer K, Wagner S, von Briesen H, Weggen S, Pietrzik CU. Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model. Alzheimer's Research & Therapy. 5: 51. PMID 24280275 DOI: 10.1186/Alzrt225 |
0.644 |
|
| 2013 |
Maier W, Bednorz M, Meister S, Roebroek A, Weggen S, Schmitt U, Pietrzik CU. LRP1 is critical for the surface distribution and internalization of the NR2B NMDA receptor subtype. Molecular Neurodegeneration. 8: 25. PMID 23866919 DOI: 10.1186/1750-1326-8-25 |
0.578 |
|
| 2013 |
Naumann EC, Göring S, Ogorek I, Weggen S, Schmidt B. Membrane anchoring γ-secretase modulators with terpene-derived moieties. Bioorganic & Medicinal Chemistry Letters. 23: 3852-6. PMID 23707256 DOI: 10.1016/J.Bmcl.2013.04.070 |
0.354 |
|
| 2013 |
Wagner T, Dieckmann M, Jaeger S, Weggen S, Pietrzik CU. Stx5 is a novel interactor of VLDL-R to affect its intracellular trafficking and processing. Experimental Cell Research. 319: 1956-72. PMID 23701949 DOI: 10.1016/J.Yexcr.2013.05.010 |
0.578 |
|
| 2012 |
Rennhack A, Jumpertz T, Ness J, Baches S, Pietrzik CU, Weggen S, Bulic B. Synthesis of a potent photoreactive acidic γ-secretase modulator for target identification in cells. Bioorganic & Medicinal Chemistry. 20: 6523-32. PMID 23000293 DOI: 10.1016/J.Bmc.2012.08.034 |
0.715 |
|
| 2012 |
Bien J, Jefferson T, Causević M, Jumpertz T, Munter L, Multhaup G, Weggen S, Becker-Pauly C, Pietrzik CU. The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species. The Journal of Biological Chemistry. 287: 33304-13. PMID 22879596 DOI: 10.1074/Jbc.M112.395608 |
0.728 |
|
| 2012 |
Zettl H, Ness J, Hähnke V, Beher D, Jumpertz T, Saric A, Baumann K, Pietrzik CU, Bulic B, Schneider G, Weggen S. Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening. Acs Chemical Biology. 7: 1488-95. PMID 22725102 DOI: 10.1021/Cb3001952 |
0.653 |
|
| 2012 |
Weggen S, Beher D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimer's Research & Therapy. 4: 9. PMID 22494386 DOI: 10.1186/Alzrt107 |
0.44 |
|
| 2012 |
Pflanzner T, Petsch B, André-Dohmen B, Müller-Schiffmann A, Tschickardt S, Weggen S, Stitz L, Korth C, Pietrzik CU. Cellular prion protein participates in amyloid-β transcytosis across the blood-brain barrier. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 32: 628-32. PMID 22293988 DOI: 10.1038/Jcbfm.2012.7 |
0.649 |
|
| 2012 |
Jumpertz T, Rennhack A, Ness J, Baches S, Pietrzik CU, Bulic B, Weggen S. Presenilin is the molecular target of acidic γ-secretase modulators in living cells. Plos One. 7: e30484. PMID 22238696 DOI: 10.1371/Journal.Pone.0030484 |
0.678 |
|
| 2012 |
Deng J, Hou H, Giunta B, Mori T, Wang YJ, Fernandez F, Weggen S, Araki W, Obregon D, Tan J. Autoreactive-Aβ antibodies promote APP β-secretase processing. Journal of Neurochemistry. 120: 732-40. PMID 22188568 DOI: 10.1111/J.1471-4159.2011.07629.X |
0.426 |
|
| 2012 |
Isbert S, Wagner K, Eggert S, Schweitzer A, Multhaup G, Weggen S, Kins S, Pietrzik CU. APP dimer formation is initiated in the endoplasmic reticulum and differs between APP isoforms. Cellular and Molecular Life Sciences : Cmls. 69: 1353-75. PMID 22105709 DOI: 10.1007/S00018-011-0882-4 |
0.792 |
|
| 2012 |
Hillmann A, Hahn S, Schilling S, Hoffmann T, Demuth HU, Bulic B, Schneider-Axmann T, Bayer TA, Weggen S, Wirths O. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiology of Aging. 33: 833.e39-50. PMID 21943956 DOI: 10.1016/J.Neurobiolaging.2011.08.006 |
0.435 |
|
| 2012 |
Bien J, Jefferson T, Causevic M, Jumpertz T, Munter LM, Multhaup G, Weggen S, Becker-Pauly C, Pietrzik C. O2-04-04: The metalloprotease meprin beta generates amino-terminally truncated beta-amyloid peptide species Alzheimer's & Dementia. 8: P242-P242. DOI: 10.1016/J.Jalz.2012.05.643 |
0.631 |
|
| 2011 |
Bulic B, Ness J, Hahn S, Rennhack A, Jumpertz T, Weggen S. Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease. Current Neuropharmacology. 9: 598-622. PMID 22798753 DOI: 10.2174/157015911798376352 |
0.443 |
|
| 2011 |
Hieke M, Ness J, Steri R, Greiner C, Werz O, Schubert-Zsilavecz M, Weggen S, Zettl H. SAR studies of acidic dual γ-secretase/PPARγ modulators. Bioorganic & Medicinal Chemistry. 19: 5372-82. PMID 21873070 DOI: 10.1016/J.Bmc.2011.08.003 |
0.322 |
|
| 2011 |
Sagi SA, Lessard CB, Winden KD, Maruyama H, Koo JC, Weggen S, Kukar TL, Golde TE, Koo EH. Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. The Journal of Biological Chemistry. 286: 39794-803. PMID 21868380 DOI: 10.1074/Jbc.M111.277228 |
0.634 |
|
| 2011 |
Jefferson T, Čaušević M, auf dem Keller U, Schilling O, Isbert S, Geyer R, Maier W, Tschickardt S, Jumpertz T, Weggen S, Bond JS, Overall CM, Pietrzik CU, Becker-Pauly C. Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. The Journal of Biological Chemistry. 286: 27741-50. PMID 21646356 DOI: 10.1074/Jbc.M111.252718 |
0.695 |
|
| 2011 |
Heneka MT, Kummer MP, Weggen S, Bulic B, Multhaup G, Münter L, Hüll M, Pflanzner T, Pietrzik CU. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Current Alzheimer Research. 8: 115-31. PMID 21345168 DOI: 10.2174/156720511795256099 |
0.782 |
|
| 2011 |
Hahn S, Brüning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik CU, Bulic B, Weggen S. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure. Journal of Neurochemistry. 116: 385-95. PMID 21091478 DOI: 10.1111/J.1471-4159.2010.07118.X |
0.8 |
|
| 2011 |
Pflanzner T, Janko MC, André-Dohmen B, Reuss S, Weggen S, Roebroek AJ, Kuhlmann CR, Pietrzik CU. LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier. Neurobiology of Aging. 32: 2323.e1-11. PMID 20630619 DOI: 10.1016/J.Neurobiolaging.2010.05.025 |
0.663 |
|
| 2010 |
Richter L, Munter LM, Ness J, Hildebrand PW, Dasari M, Unterreitmeier S, Bulic B, Beyermann M, Gust R, Reif B, Weggen S, Langosch D, Multhaup G. Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proceedings of the National Academy of Sciences of the United States of America. 107: 14597-602. PMID 20679249 DOI: 10.1073/Pnas.1003026107 |
0.545 |
|
| 2010 |
Zettl H, Weggen S, Schneider P, Schneider G. Exploring the chemical space of gamma-secretase modulators. Trends in Pharmacological Sciences. 31: 402-10. PMID 20591508 DOI: 10.1016/J.Tips.2010.05.007 |
0.503 |
|
| 2010 |
Hieke M, Ness J, Steri R, Dittrich M, Greiner C, Werz O, Baumann K, Schubert-Zsilavecz M, Weggen S, Zettl H. Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity. Journal of Medicinal Chemistry. 53: 4691-700. PMID 20503989 DOI: 10.1021/Jm1003073 |
0.444 |
|
| 2010 |
Reekmans SM, Pflanzner T, Gordts PL, Isbert S, Zimmermann P, Annaert W, Weggen S, Roebroek AJ, Pietrzik CU. Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis. Cellular and Molecular Life Sciences : Cmls. 67: 135-45. PMID 19856143 DOI: 10.1007/S00018-009-0171-7 |
0.591 |
|
| 2010 |
Richter L, Munter L, Ness J, Hildebrand PW, Joshi M, Unterreitmeier S, Bulic B, Beyermann M, Gust R, Reif B, Weggen S, Langosch D, Multhaup G. Aβ42-lowering compounds interfere with APP transmembrane sequence dimerization Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.1948 |
0.369 |
|
| 2009 |
Jäger S, Leuchtenberger S, Martin A, Czirr E, Wesselowski J, Dieckmann M, Waldron E, Korth C, Koo EH, Heneka M, Weggen S, Pietrzik CU. alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation. Journal of Neurochemistry. 111: 1369-82. PMID 19804379 DOI: 10.1111/J.1471-4159.2009.06420.X |
0.816 |
|
| 2009 |
Kummer MP, Maruyama H, Huelsmann C, Baches S, Weggen S, Koo EH. Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase. The Journal of Biological Chemistry. 284: 2296-306. PMID 19047044 DOI: 10.1074/Jbc.M808904200 |
0.772 |
|
| 2009 |
Leuchtenberger S, Maler J, Czirr E, Ness J, Lichtenthaler SF, Esselmann H, Pietrzik CU, Wiltfang J, Weggen S. Nonsteroidal anti-inflammatory drugs and ectodomain shedding of the amyloid precursor protein. Neuro-Degenerative Diseases. 6: 1-8. PMID 18349521 DOI: 10.1159/000121391 |
0.793 |
|
| 2009 |
Lehmann S, Bruening T, Ness J, Czirr E, Bulic B, Pietrzik CU, Weggen S. P3-271: Presenilin-1 (PS1) and amyloid precursor protein (APP) mutations present in mouse models of Alzheimer's disease in their response to γ-secretase inhibitors and modulators Alzheimer's & Dementia. 5: P422-P423. DOI: 10.1016/J.Jalz.2009.04.942 |
0.814 |
|
| 2009 |
Ness JS, Riemenschneider MJ, Baches S, Eriksen JL, Pietrzik CU, Reifenberger G, Weggen S. P4-244: Progranulin (GRN), a protein mutated in frontotemporal dementia with ubiquitin-positive inclusions (FTLD-U), is abundantly expressed in human gliomas Alzheimer's & Dementia. 5: P502-P502. DOI: 10.1016/J.Jalz.2009.04.710 |
0.603 |
|
| 2008 |
Waldron E, Heilig C, Schweitzer A, Nadella N, Jaeger S, Martin AM, Weggen S, Brix K, Pietrzik CU. LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiology of Disease. 31: 188-97. PMID 18559293 DOI: 10.1016/J.Nbd.2008.04.006 |
0.702 |
|
| 2008 |
Waldron E, Isbert S, Kern A, Jaeger S, Martin AM, Hébert SS, Behl C, Weggen S, De Strooper B, Pietrzik CU. Increased AICD generation does not result in increased nuclear translocation or activation of target gene transcription. Experimental Cell Research. 314: 2419-33. PMID 18559276 DOI: 10.1016/J.Yexcr.2008.05.003 |
0.656 |
|
| 2008 |
Czirr E, Cottrell BA, Leuchtenberger S, Kukar T, Ladd TB, Esselmann H, Paul S, Schubenel R, Torpey JW, Pietrzik CU, Golde TE, Wiltfang J, Baumann K, Koo EH, Weggen S. Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. The Journal of Biological Chemistry. 283: 17049-54. PMID 18426795 DOI: 10.1074/Jbc.M802912200 |
0.824 |
|
| 2008 |
Martin AM, Kuhlmann C, Trossbach S, Jaeger S, Waldron E, Roebroek A, Luhmann HJ, Laatsch A, Weggen S, Lessmann V, Pietrzik CU. The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. The Journal of Biological Chemistry. 283: 12004-13. PMID 18321860 DOI: 10.1074/Jbc.M707607200 |
0.593 |
|
| 2008 |
Narlawar R, Pickhardt M, Leuchtenberger S, Baumann K, Krause S, Dyrks T, Weggen S, Mandelkow E, Schmidt B. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease? Chemmedchem. 3: 165-72. PMID 17943713 DOI: 10.1002/Cmdc.200700218 |
0.415 |
|
| 2008 |
Weggen S. S4-04-04: γ-secretase modulators: Effects on Aβ production and therapeutic potential for familial Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.496 |
0.394 |
|
| 2008 |
Czirr E, Cottrell BA, Serneels L, Leuchtenberger S, Schubenel R, Torpey JW, Esselmann H, Pietrzik CU, Wiltfang J, DeStrooper B, Baumann K, Koo EH, Weggen S. P4-192: Mechanism of γ-secretase cleavage: Evidence for independent generation of Aβ42 and Aβ38 peptide species Alzheimer's & Dementia. 4: T727-T728. DOI: 10.1016/J.Jalz.2008.05.2259 |
0.798 |
|
| 2008 |
Pietrzik CU, Jaeger S, Wesselowski J, Cirr E, Korth C, Weggen S, Koo EH, Pietrzik KF. P3-344: γ-secretase-dependent APP processing occurs either at the plasma membrane or in the endocytic compartments independent of the APP wild-type or APP Swedish variant Alzheimer's & Dementia. 4: T622-T622. DOI: 10.1016/J.Jalz.2008.05.1913 |
0.708 |
|
| 2007 |
Weggen S, Rogers M, Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends in Pharmacological Sciences. 28: 536-43. PMID 17900710 DOI: 10.1016/J.Tips.2007.09.004 |
0.489 |
|
| 2007 |
Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH, Pietrzik CU, Baumann K, Weggen S. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. The Journal of Biological Chemistry. 282: 24504-13. PMID 17573346 DOI: 10.1074/Jbc.M700618200 |
0.819 |
|
| 2007 |
Weggen S, Czirr E, Leuchtenberger S, Eriksen J. Nonsteroidal anti-inflammatory drugs (NSAIDs) and derived Aβ42-lowering molecules for treatment and prevention of Alzheimer's disease (AD) Pharmacological Mechanisms in Alzheimer's Therapeutics. 167-193. DOI: 10.1007/978-0-387-71522-3_11 |
0.722 |
|
| 2006 |
Leuchtenberger S, Beher D, Weggen S. Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. Current Pharmaceutical Design. 12: 4337-55. PMID 17105431 DOI: 10.2174/138161206778793029 |
0.559 |
|
| 2006 |
Czirr E, Weggen S. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. Neuro-Degenerative Diseases. 3: 298-304. PMID 17047371 DOI: 10.1159/000095270 |
0.794 |
|
| 2006 |
Leuchtenberger S, Kummer MP, Kukar T, Czirr E, Teusch N, Sagi SA, Berdeaux R, Pietrzik CU, Ladd TB, Golde TE, Koo EH, Weggen S. Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42. Journal of Neurochemistry. 96: 355-65. PMID 16300630 DOI: 10.1111/J.1471-4159.2005.03553.X |
0.811 |
|
| 2005 |
Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nature Medicine. 11: 545-50. PMID 15834426 DOI: 10.1038/Nm1235 |
0.675 |
|
| 2004 |
Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 4259-65. PMID 15115822 DOI: 10.1523/Jneurosci.5451-03.2004 |
0.719 |
|
| 2004 |
Weggen S, Berdeaux R, Kummer MP, Birkenfeld J, Sagi SS, Golde TE, Koo EH. P4-380 Inhibitors of the RHO effector RHO-kinase (rock) modulate Aβ secretion but lack selectivity for Aβ42 Neurobiology of Aging. 25: S583. DOI: 10.1016/S0197-4580(04)81938-9 |
0.741 |
|
| 2004 |
Pietrzik CU, Jaeger S, Yoon I, Busse T, Weggen S, Koo EH. P3-296 FE65 constitutes the functional link between the LDL receptor-related protein (LRP) and APP Neurobiology of Aging. 25: S439. DOI: 10.1016/S0197-4580(04)81446-5 |
0.684 |
|
| 2003 |
Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. The Journal of Clinical Investigation. 112: 440-9. PMID 12897211 DOI: 10.1172/Jci18162 |
0.684 |
|
| 2003 |
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. The Journal of Biological Chemistry. 278: 31831-7. PMID 12805356 DOI: 10.1074/Jbc.M303592200 |
0.742 |
|
| 2003 |
Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. The Journal of Biological Chemistry. 278: 31825-30. PMID 12805355 DOI: 10.1074/Jbc.M303588200 |
0.622 |
|
| 2003 |
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. The Journal of Biological Chemistry. 278: 30748-54. PMID 12777371 DOI: 10.1074/Jbc.M304824200 |
0.779 |
|
| 2002 |
Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. The Embo Journal. 21: 5691-700. PMID 12411487 DOI: 10.1093/Emboj/Cdf568 |
0.77 |
|
| 2002 |
Golde TE, Eriksen JL, Weggen S, Sagi SA, Koo EH. Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease Drug Development Research. 56: 415-420. DOI: 10.1002/Ddr.10093 |
0.659 |
|
| 2001 |
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414: 212-6. PMID 11700559 DOI: 10.1038/35102591 |
0.83 |
|
| 1999 |
Diehlmann A, Ida N, Weggen S, Grünberg J, Haass C, Masters CL, Bayer TA, Beyreuther K. Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. Journal of Neuroscience Research. 56: 405-19. PMID 10340748 DOI: 10.1002/(Sici)1097-4547(19990515)56:4<405::Aid-Jnr8>3.0.Co;2-F |
0.443 |
|
| 1999 |
Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA. Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease. Acta Neuropathologica. 97: 113-8. PMID 9928821 DOI: 10.1007/S004010050963 |
0.51 |
|
| 1998 |
Weggen S, Diehlmann A, Buslei R, Beyreuther K, Bayer TA. Prominent expression of presenilin-1 in senile plaques and reactive astrocytes in Alzheimer's disease brain. Neuroreport. 9: 3279-83. PMID 9831464 |
0.333 |
|
| 1997 |
Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K, Multhaup G. Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease. Acta Neuropathologica. 94: 519-24. PMID 9444352 DOI: 10.1007/S004010050745 |
0.522 |
|
| 1997 |
Bayer TA, Weggen S, Hesse L, Cappai R, Masters CL, Beyreuther K, Multhaup G. Distribution of amyloid precursor-like protein 2 in normal and Alzheimer's disease hippocampal formation Alzheimer's Research. 3: 199-203. |
0.321 |
|
| Show low-probability matches. |